Prolia Treatment - Case Study 3 | Osteoporosis | Amgen

Is this your next Prolia® patient?

78-year-old woman with comorbidities and poor persistence with medication.
78-year-old woman with comorbidities and poor persistence with medication
  • Previous fracture of the hip 3 years ago
  • Began treatment with an oral bisphosphonate 1 year ago; unsure of her persistence because of forgetfulness in everyday life
  • Comorbidities include type 2 diabetes, high blood pressure and elevated cholesterol

Criteria: Why should she transition to Prolia®?

  • Patients who have experienced a prior fracture are at increased risk of future fracture1*
  • Good treatment persistence is associated with a greater reduction in fracture risk2
  • Infrequent dosing and convenient administration can improve adherence to medications in the elderly with comorbidities3,4†
  • Prolia® reduces the risk of subsequent fracture by 39% vs placebo5
  • 10 years of Prolia® is associated with a favourable benefit/risk profile:6
    • Sustained low incidence of fractures
    • Well tolerated
  • Prolia® is associated with better persistence than oral bisphosphonates7–10
  • Patients prefer the convenient twice-yearly subcutaneous administration of Prolia® injections over oral bisphosphonates11–13
*Data from a statistical synthesis of the literature on the risk of future fracture, given a history of prior fracture, showed that postmenopausal women with prior fractures had 2.0 times the risk of subsequent fracture compared with women without prior fracture (95% CI: 1.8–2.1). Pooled associations showed that postmenopausal women with prior hip fracture were 2.4 times more likely to suffer another fracture at any site (95% CI: 1.9–3.2).1
Bisphosphonates often place specific requirements on patients to achieve maximal uptake, including having to stand upright for at least 30–60 minutes and refrain from consuming food, drink or supplements for at least 30 minutes after administration.14
CI: confidence interval.
  1. Klotzbuecher CM, et al. J Bone Miner Res. 2000;15:721–39.
  2. Cotte FE, et al. Clin Ther. 2008;30:2410–22.
  3. Haehl K. The importance of convenient dosing formulation for elderly patients. January 2016. Available at: Articles/183038-The-Importance-of-Convenient-Dosing-Formulations-for-Elderly-Patients. Last accessed May 2021.
  4. Prolia® (denosumab) Summary of Product Characteristics. Amgen. Last revised December 2020.
  5. Palacios S, et al. Climacteric. 2015;18:805–12.
  6. Bone HG, et al. Lancet Diabetes Endocrinol. 2017;5:513–23.
  7. Reyes C, et al. Osteoporos Int. 2017;28:2297–3004.
  8. Hadji P, et al. Osteoporos Int. 2016;27:2967–78
  9. Karlsson L, et al. Osteoporos Int. 2015;26:2401–11.
  10. Durden E, et al. Arch Osteoporos. 2017;12:22–30.
  11. Freemantle N, et al. Osteoporos Int. 2012;23:317–26.
  12. Palacios S, et al. J Clin Endocrinol Metab. 2015;100:E487–92.
  13. Kendler DL, et al. Osteoporos Int. 2011;22:1725–35.
  14. Abramsson L and Gustafsson M. Pharmacy (Basel). 2018;6:20.


The information contained in this site is for healthcare professionals only

I am a patient
I am a member of the public